Expanded Access Policy

At Caladrius Biosciences, we are combining state-of-the-art science with the body’s intricate biologic systems, and are working to leverage the body’s  development of cell capabilities with complex and specific functions. We believe that each study we perform expands the foundations of cell therapy and biologic science and believe that our research and discovery will have meaningful and lasting influence. We pledge to use our experience and knowledge to advance science, research and development. Caladrius encourages awareness of and participation in its clinical trials and believes that participating in clinical trials is the best way for patients to access buysoma investigational drugs prior to regulatory approval.

Currently, Caladrius does not make its unapproved drugs available on an expanded access basis. Caladrius does, however, encourage interested individuals to contact the company regarding potential participation in its clinical trials.

If you have any questions regarding potential participation in Caladrius’s clinical trials or about this expanded access policy, please contact us by phone at 908-842-0084 or by email at jmenditto@caladrius.com.

As authorized by the 21st Century Cures Act, Caladrius Biosciences may revise this policy at any time.